A Phase I/II. Open-Label, Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects.

Trial Profile

A Phase I/II. Open-Label, Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Orteronel (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jun 2013 Planned end date changed from 1 Feb 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 23 Jan 2013 Planned end date changed from 1 Aug 2014 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top